Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
VWAGY Volkswagen AG
MLVF Malvern Bancorp Inc
GBCI Glacier Bancorp Inc
Go

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
$2.39
Day's Change
-0.01 (-0.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.60
Day's Low
2.17
Volume
(Heavy Day)
Volume:
816,733

10-day average volume:
173,568
816,733

CELH SHAREHOLDER ALERT: Jakubowitz Law Reminds Celsius Shareholders of a Lead Plaintiff Deadline of May 16, 2022

5:45 am ET May 13, 2022 (PR Newswire) Print

Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Celsius Holdings, Inc. (NASDAQ: CELH).

To receive updates on the lawsuit, fill out the form:https://claimyourloss.com/securities/celsius-holdings-inc-loss-submission-form/?id=27148&from=4

The lawsuit seeks to recover losses for shareholders who purchased Celsius between August 12, 2021 and March 1, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until May 16, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Celsius Holdings, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly recorded expenses for non-cash share-based compensation for second and third quarters of 2021; (2) as a result, the Company's financial statements for those periods would be restated, including to report a net loss for the third quarter of 2021; (3) there was a material weakness in Celsius's internal controls over financial reporting; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887

https://c212.net/c/img/favicon.png?sn=NY56527&sd=2022-05-13

View original content:https://www.prnewswire.com/news-releases/celh-shareholder-alert-jakubowitz-law-reminds-celsius-shareholders-of-a-lead-plaintiff-deadline-of-may-16-2022-301546637.html

SOURCE Jakubowitz Law

https://rt.prnewswire.com/rt.gif?NewsItemId=NY56527&Transmission_Id=202205130545PR_NEWS_USPR_____NY56527&DateId=20220513

comtex tracking

COMTEX_407135763/1005/2022-05-13T05:45:05

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.